A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback